Aquestive Therapeutics (AQST) Profit After Tax (2017 - 2025)
Historic Profit After Tax for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$15.4 million.
- Aquestive Therapeutics' Profit After Tax fell 3420.8% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 9600.2%. This contributed to the annual value of -$44.1 million for FY2024, which is 46082.59% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Profit After Tax is -$15.4 million, which was down 3420.8% from -$13.5 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Profit After Tax ranged from a high of $8.1 million in Q1 2023 and a low of -$28.9 million during Q4 2021
- In the last 5 years, Aquestive Therapeutics' Profit After Tax had a median value of -$12.8 million in 2024 and averaged -$12.0 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Profit After Tax surged by 16102.87% in 2023, and later crashed by 46555.28% in 2024.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Profit After Tax stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then soared by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then increased by 9.43% to -$15.4 million in 2025.
- Its Profit After Tax stands at -$15.4 million for Q3 2025, versus -$13.5 million for Q2 2025 and -$22.9 million for Q1 2025.